1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
Doctors at EJK Duisburg in Germany Successfully Treated Respiratory Distress Syndrome in a 55-Year-Old Male Suffering from Refractory Cardiogenic Shock
TUCSON, Ariz. – August 21, 2013 – SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that doctors at EJK Duisburg in Germany have published the first case report detailing use of single-site cannulation with extracorporeal membrane oxygenation (ECMO) to successfully treat adult respiratory distress syndrome in a patient implanted with the SynCardia temporary Total Artificial Heart. The case report was published in the August issue of the Journal of Cardiothoracic Surgery.
Before the Total Artificial Heart implant, the 55-year-old patient was supported by veno-arterial ECMO due to refractory cardiogenic shock and severe respiratory failure. Once the Total Artificial Heart was implanted, the patient was weaned from extracorporeal circulation. However, due to pre-existing respiratory failure, doctors decided to implement veno-venous ECMO using a single-site bicaval dual-lumen catheter placed in the right internal jugular vein instead of conventional dual-site cannulation.
“In this context single-site veno-venous cannulation proved to have numerous advantages: it is simple to perform, it minimizes the risk of cannula dislodgement during patient care, reduces the risk of catheter related infections and finally allows early sternum closure,” according to the report written by Dr. Sotirios Spiliopoulos, surgeons Dr. Guenes Dogan and Dr. Dilek Guersoy, intensivist Dr. Maria Rosario Serrano and Prof. Reiner Koerfer and Prof. Gero Tenderich, the implanting surgeon.
“Single-site venous cannulation could be a reasonable alternative to conventional cannulation for ECMO support in SynCardia Total Artificial Heart patients with an adult respiratory distress syndrome,” the report concluded.
“This is an excellent case report,” said Dr. Francisco Arabia, who has implanted more than 100 SynCardia Total Artificial Hearts. Arabia co-authored one of the articles cited in the August case report. That article dealt with parallel ECMO and artificial heart applications. He has proctored the first implant at more than a dozen hospitals qualifying these centers of excellence to become SynCardia Certified Centers.
About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.
Janelle Drumwright, firstname.lastname@example.org, (520) 547-7463